Lucira Health, Inc. (LHDX) Research

Lucira Health, Inc. is a medical technology enterprise dedicated to the development and commercialization of diagnostic test kits for infectious diseases. The company has innovated a platform capable of providing molecular testing capabilities. Among its current product offerings is the LUCIRA COVID-19 All-In-One Test Kit, and it is also progressing with the development of diagnostic solutions for influenza A and B viruses. Lucira Health holds a patent license agreement with Eiken Chemical Co., Ltd., alongside technical and manufacturing service agreements with Jabil, Inc. and Jabil MSA, respectively. Founded in 2013, the company operated as DiAssess Inc. until January 2020 when it rebranded to Lucira Health, Inc. Its main offices are situated in Emeryville, California.

Market snapshot

Symbol
LHDX
Price
$0.45
Day change
0.00%
Market cap
$18.4M
P/E ratio
-0.24x
52-week range
0.108-4.35
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Chembio Diagnostics, Inc. (CEMI)
  • Conformis, Inc. (CFMS)
  • COSCIENS Biopharma Inc. (CSCI)
  • Dole plc (DOLE)
  • Elutia Inc. (ELUT)
  • Enzo Biochem, Inc. (ENZB)
  • MetaVia Inc. (MTVA)
  • Nymox Pharmaceutical Corporation (NYMXF)

Recent insider activity

  • Engelson Erik T. — M-Exempt (574666 shares) on 2023-03-03
  • Engelson Erik T. — S-Sale (574666 shares) on 2023-03-03
  • Engelson Erik T. — S-Sale (60000 shares) on 2023-03-03
  • Engelson Erik T. — M-Exempt (574666 shares) on 2023-03-03
  • Narido Richard Clavano — S-Sale (10674 shares) on 2023-03-03

Open Lucira Health, Inc. (LHDX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.